Sonoma Pharmaceuticals (SNOA) Downgraded by Zacks Investment Research to Hold
Zacks Investment Research cut shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) from a buy rating to a hold rating in a research report sent to investors on Friday.
According to Zacks, “Sonoma Pharmaceuticals operates as a pharmaceutical company. It develops and markets solutions for the treatment of dermatological conditions, animal health and advanced tissue care. The company operates primarily in United States, Latin America and Europe. Sonoma Pharmaceuticals formerly known as Oculus Innovative Sciences and is headquatered in Petaluma, California. “
SNOA has been the subject of a number of other research reports. Maxim Group boosted their target price on Sonoma Pharmaceuticals from $10.00 to $11.00 and gave the stock a buy rating in a research report on Friday, November 10th. Benchmark started coverage on Sonoma Pharmaceuticals in a research report on Thursday, December 28th. They set a speculative buy rating and a $10.00 target price for the company.
Sonoma Pharmaceuticals (NASDAQ:SNOA) traded down $0.07 during mid-day trading on Friday, hitting $5.49. The stock had a trading volume of 10,677 shares, compared to its average volume of 30,340. The company has a market capitalization of $24.09, a P/E ratio of -2.76 and a beta of 1.19. Sonoma Pharmaceuticals has a 12 month low of $4.16 and a 12 month high of $8.25. The company has a current ratio of 5.37, a quick ratio of 4.56 and a debt-to-equity ratio of 0.01.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.